April 19, 2018
Chugai Pharmaceutical’s anti-PD-L1 antibody Tecentriq (atezolizumab) was launched on April 18 to mark the debut of the PD-L1 class in Japan’s lung cancer space as a raft of new drugs joined the NHI price list on the same day, with...read more